Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX HELSINKI LTD.  >  Orion Oyj    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.
  • The company is one of the best yield companies with high dividend expectations.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • With an enterprise value anticipated at 4.8 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ORION OYJ1.73%6 506
JOHNSON & JOHNSON2.08%422 918
ROCHE HOLDING AG0.99%301 476
NOVARTIS AG-0.16%214 006
MERCK & CO., INC.0.45%207 893
PFIZER INC.-0.16%204 271
ABBVIE INC.4.18%197 080
ELI LILLY AND COMPANY10.57%169 250
NOVO NORDISK A/S2.48%165 077
BRISTOL-MYERS SQUIBB COMPAN..6.43%149 189
AMGEN INC.5.11%140 687
ASTRAZENECA PLC3.21%135 863
SANOFI2.88%123 562
GLAXOSMITHKLINE PLC3.83%95 210
CHUGAI PHARMACEUTICAL CO., ..7.11%91 993
JIANGSU HENGRUI MEDICINE CO..-1.46%90 348
More Results
Financials
Sales 2020 1 090 M 1 316 M 1 316 M
Net income 2020 236 M 285 M 285 M
Net cash 2020 134 M 162 M 162 M
P/E ratio 2020 22,8x
Yield 2020 3,89%
Capitalization 5 497 M 6 647 M 6 641 M
EV / Sales 2020 4,92x
EV / Sales 2021 5,03x
Nbr of Employees 3 320
Free-Float 86,5%
Upcoming event on ORION OYJ
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes